Prostatic Neoplasms, Castration-ResistantPhase 1NCT05743621
Study of TVB-2640 in Men With Metastatic Castration-Resistant Prostate Cancer
A Phase 1 study testing TVB-2640 and Enzalutamide in people with Prostatic Neoplasms, Castration-Resistant, run by Weill Medical College of Cornell University at 1 site in United States.
Trial summary
The purpose of this study is to determine what effects (good and bad) Enzalutamide and TVB-2640 have in the treatment of prostate cancer whose prostate cancer has spread to other parts of their body and that has not gotten better with previous treatment. This study is a Phase I clinical trial. Read more about this study
- Who is it for?
- Ages 18 years and older, men only
- Conditions the study is for
- Prostatic Neoplasms, Castration-Resistant
- What is being tested?
- TVB-2640 and Enzalutamide
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 8 participants
- Where
- 1 siteUnited States
- Study dates
- 20 Nov 2023to 25 Jan 2028
- Phase
- Phase 1
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- Men only
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age >18 years
- Documented histological or cytological diagnosis of PC
- Evidence of metastatic PC on imaging (bone scan and/or CT/MRI scan)
- Diagnosis of progressive metastatic, castration resistant prostate cancer
- Potential participant must be planning to receive Enzalutamide as their first line of therapy for castration resistant prostate cancer or have previously received up to one line of Abiraterone or an androgen receptor antagonist
- Willing to undergo a tumor biopsy prior to beginning therapy, if recent tissue samples are not available
Show all 13Show fewer
- Willing to undergo a tumor biopsy of at least one metastatic site or primary prostate after ~4-6 weeks of therapy with both agents
- Participants without prior orchiectomy must be currently taking and willing to continue luteinizing hormone-releasing hormone (LHRH) analogue (agonist or antagonist) therapy until permanent discontinuation of study treatment
- ECOG performance status of 0-1
- Recovery to baseline or ≤ Grade 1 CTCAE v5 from toxicities related to any prior treatments, unless specified below AE(s) are clinically nonsignificant and/or stable on supportive therapy
- Adequate organ and marrow function, based upon laboratory criteria within 14 days before first dose of study treatment
- Sexually active, fertile participants and their partners must agree to use medically accepted methods of contraception (e.g., barrier methods, including male condom with spermicide during the course of the study and for 4 months after the last dose of study treatment
- Capable of understanding and complying with the protocol requirements and must have signed the informed consent document
Who cannot join
- Receipt of any type of biologic, or other systemic anticancer therapy (including investigational) except agents within 4 weeks before first dose of study treatment. Anti-resorptive bone agents are also allowed.
- Radiation therapy for bone metastasis within 2 weeks, any other radiation therapy within 4 weeks before first dose of study treatment. Systemic treatment with radionuclides within 6 weeks before the first dose of study treatment. Participants with clinically relevant ongoing complications from prior radiation therapy are not eligible.
- Prior exposure to taxane chemotherapy
- History of pneumonitis
- Known brain metastases or cranial epidural disease unless adequately treated with radiotherapy and/or surgery (including radiosurgery) and stable for at least 4 weeks prior to first dose of study treatment after radiotherapy or at least 4 weeks prior to first dose of study treatment after major surgery (e.g., removal or biopsy of brain metastasis). Participants must have complete wound healing from major surgery or minor surgery before first dose of study treatment. Eligible participants must be neurologically asymptomatic and without corticosteroid treatment for neurological indications at the time of first dose of study treatment.
- Participants with clinically significant dry eye or corneal abnormalities
Show all 19Show fewer
- Currently taking certain anticoagulation medications, such as coumarin agents (e.g., warfarin), direct thrombin inhibitors (e.g., dabigatran), direct factor Xa inhibitor betrixaban, or platelet inhibitors (e.g., clopidogrel)
- Participant has prothrombin time (PT)/INR or partial thromboplastin time (PTT) test ≥ 1.3 X the laboratory ULN within 30 days before the first dose of study treatment.
- Participants should not receive strong CYP2C8 or strong P-gp inhibitors; strong CYP3A4 or CYP2C8 inducers; and strong CYP3A4, CYP2C9 and CYP2C19 substrates while participating in the trial, unless utilized with caution to treat a drug-related AE when no alternative is available and discussed with the Medical Monitor.
- Participant has uncontrolled, significant intercurrent or recent Cardiovascular disorders including, but not limited to, the following conditions:
- Congestive heart failure New York Heart Association Class 3 or 4, unstable angina pectoris, serious cardiac arrhythmias.
- Uncontrolled hypertension defined as sustained blood pressure (BP) >140 mm Hg systolic or >90 mm Hg diastolic despite optimal antihypertensive treatment.
- Stroke (including transient ischemic attack [TIA]), myocardial infarction (MI), or other ischemic event, or thromboembolic event (e.g. deep venous thrombosis, pulmonary embolism) within 6 months before first dose.
- Corrected QT interval calculated by the Fridericia formula (QTcF) > 470 ms per electrocardiogram (ECG) within 28 days before first dose of study treatment.
- Inability to swallow tablets.
- Use of herbal products that may decrease PSA levels within 4 weeks prior to enrollment
- Previously identified allergy or hypersensitivity to components of the study treatment formulations.
- Diagnosis of another type of cancer within 2 years before first dose of study treatment, except for superficial skin cancers, or localized, low-grade tumors deemed cured and not treated with systemic therapy.
- Any serious and/or unstable pre-existing medical, psychiatric disorder or other conditions that could interfere with participant's safety, obtaining informed consent or compliance to the study procedures.
Trial locations and contacts
1 site in 1 country.
United States1 site
Weill Cornell Medicine/NewYork-Presbyterian Hospital
New York, New York, 10021
About this study
Official title: A Phase I, Open-Label, Dose-Finding Study of TVB-2640 Administered in Combination With Enzalutamide (Xtandi) in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
The purpose of this study is to determine what effects (good and bad) Enzalutamide and TVB-2640 have in the treatment of prostate cancer whose prostate cancer has spread to other parts of their body and that has not gotten better with previous treatment. This study is a Phase I clinical trial. Phase I clinical trials test the side effects of an investigational drug or an investigational combination with another drug. "Investigational" means that the drug is still being studied and research doctors are trying to find out more about it. Although Enzalutamide is already being used to treat men with prostate cancer, combining Enzalutamide with TVB-2640 together in patients with prostate cancer is considered experimental. This research study is being done because additional effective treatments are needed for prostate cancer that has spread and is growing despite hormone suppression. By doing this study, the investigators hope to learn if combining Enzalutamide with TVB-2640 can be done safely. Participation in this research will last about 12 to 24 months after enrollment.
Read the detailed description
This phase I, open-label, dose-escalation study is designed to evaluate the dose limiting toxicities (DLTs) and maximum-tolerated dose (MTD) of TVB-2640 plus Enzalutamide and establish the TVB-2640 dose recommended for further investigation in phase 2 (i.e., recommended phase 2 dose [RP2D]). Patients with a confirmed histological or cytological diagnosis of prostate cancer (PC), evidence of metastatic PC on imaging (bone scan and/or CT/MRI scan), serum testosterone <50 ng/dl, who had progressed on androgen-depletion therapy (ADT), with documented progressive metastatic castration-resistant prostate cancer (mCRPC) based on Prostate Cancer Working Group 3 (PCWG3) criteria and no previously treatment with cytotoxic chemotherapy are eligible. This study represents the first clinical evaluation of TVB-2640 in combination with Enzalutamide. All patients will receive Enzalutamide monotherapy at the approved dose of 160 mg once daily for 28 days to reach the steady state as determined by measuring Enzalutamide and des-methyl-Enzalutamide levels. Participants who complete the Enzalutamide run-in period will begin oral TVB-2640 at the dose of 100 mg. The dose escalation scheme will be the Bayesian optimal interval (BOIN) design with additional dose levels of 100 mg, 150mg, 200 mg, 250 mg, and 300mg daily. The maximum sample size for the phase I will be 30 patients and the target DLT rate is 25% or less and a maximum of 9 patients at any dose level.
- Being tested
- TVB-2640, Enzalutamide
- Keywords
- Metastatic Castration-Resistant Prostate Cancer, FASN Inhibitor
- Medical subject headings
- Prostatic Neoplasms, Castration-Resistant
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
TVB-2640Drug
TVB- 2640 at 100 mg, 150mg, 200 mg, 250 mg, or 300mg daily, orally; dose determined by BOIN dose escalation per the protocol
EnzalutamideDrug
Also called Xtandi
160 mg daily PO
| Study group | Role | What they receive |
|---|---|---|
| TVB-2640 in combination with Enzalutamide | Experimental | Not described Receives: Drug: TVB-2640; Drug: Enzalutamide |
What is being measured
The primary outcome is the main question the study is designed to answer.
Optimal dose of TVB-2640 in combination with Enzalutamide, as determined by the maximum tolerated dose (MTD)
The maximum tolerated dose (MTD) is defined as the highest dose level at which ≤1 patient experiences a dose-limiting toxicity, as defined in the protocol (DLT). Once all the patients are accrued, the MTD will be determined by performing isotonic regression on the pooled data.
Measured: From start of treatment to 28 days after start of TVB-2640 treatment
Secondary outcomes (19)
Number of adverse events (evaluated using the NCI CTCAE v5.0) of different doses of TVB-2640 in combination with Enzalutamide
All observed AEs will be tabulated and reported as relative frequencies (i.e., fraction of patients with that AE). This will be done by AE and maximum grade experienced within a patient. The fraction of patients with each AE by grade will be estimated with a binomial point estimate and corresponding 95% binomial confidence interval (CI). AEs will be collected until 30 days following the last dose of study drug. AEs will be reported for each different dose of TVB-2640 given.
Measured: 12 months
Mean TVB-2640 total exposure (as measured by the area under the drug serum concentration vs. the time from administration curve [AUC])
Peripheral blood will be drawn at:
Day 28:
- Pre- enza dose
- Post-dose
- 1 hours (±5 min)
- 2 hours (±5 min)
- 4 hours (±30 min)
Days 36-37:
- Pre-TVB-2640 dose
- Post-dose
- 2 hours (±5 min)
- 4 hours (±30 min)
- 6 hours (±30 min)
- 8 hours (±30 min)
- 24-hours (±1 hour)
Days 43-44:
- Pre-TVB-2640 dose
- Post-dose
- 30 minutes (±5 min)
- 1 hour (±5 min)
- 2 hours (±5 min)
- 4 hours (±30 min)
- 6 hours (±30 min)
- 8 hours (±30 min)
- 24-hours (±1 hour)
Days 50-51:
- Pre-TVB-2640 dose
- Post-dose
- 30 minutes (±5 min)
- 1 hour (±5 min)
- 2 hours (±5 min)
- 4 hours (±30 min)
- 6 hours (±30 min)
- 8 hours (±30 min)
- 24-hours (±1 hour)
Measured: Day 28; Days 36-37; Days 43-44; Days 50-51
Mean Enzalutamide total exposure (as measured by the area under the drug serum concentration vs. the time from administration curve [AUC])
Peripheral blood will be drawn at:
Day 28:
- Pre- enza dose
- Post-dose
- 1 hours (±5 min)
- 2 hours (±5 min)
- 4 hours (±30 min)
Days 36-37:
- Pre-TVB-2640 dose
- Post-dose
- 2 hours (±5 min)
- 4 hours (±30 min)
- 6 hours (±30 min)
- 8 hours (±30 min)
- 24-hours (±1 hour)
Days 43-44:
- Pre-TVB-2640 dose
- Post-dose
- 30 minutes (±5 min)
- 1 hour (±5 min)
- 2 hours (±5 min)
- 4 hours (±30 min)
- 6 hours (±30 min)
- 8 hours (±30 min)
- 24-hours (±1 hour)
Days 50-51:
- Pre-TVB-2640 dose
- Post-dose
- 30 minutes (±5 min)
- 1 hour (±5 min)
- 2 hours (±5 min)
- 4 hours (±30 min)
- 6 hours (±30 min)
- 8 hours (±30 min)
- 24-hours (±1 hour)
Measured: Day 28; Days 36-37; Days 43-44; Days 50-51
Mean maximum serum concentration (Cmax) of TVB-2640
Peripheral blood will be drawn at the following times:
Day 28:
- Pre- enza dose
- 1 hours (±5 min) post-dose
- 2 hours (±5 min) post-dose
- 4 hours (±30 min) post-dose
Days 36-37:
- Before TVB-2640 administration
- 2 hours (±5 min) post-dose
- 4 hours (±30 min) post-dose
- 6 hours (±30 min) post-dose
- 8 hours (±30 min) post-dose
- 24-hours (±1 hour) post-dose
Days 43-44:
- Before TVB-2640 administration
- 30 minutes (±5 min) post-dose
- 1 hour (±5 min) post-dose
- 2 hours (±5 min) post-dose
- 4 hours (±30 min) post-dose
- 6 hours (±30 min) post-dose
- 8 hours (±30 min) post-dose
- 24-hours (±1 hour) post-dose
Days 50-51:
- Before TVB-2640 administration
- 30 minutes (±5 min) post-dose
- 1 hour (±5 min) post-dose
- 2 hours (±5 min) post-dose
- 4 hours (±30 min) post-dose
- 6 hours (±30 min) post-dose
- 8 hours (±30 min) post-dose
- 24-hours (±1 hour) post-dose
Measured: Day 28; Days 36-37; Days 43-44; Days 50-51
Mean maximum serum concentration (Cmax) of Enzalutamide
Peripheral blood will be drawn at the following times:
Day 28:
- Pre- enza dose
- 1 hours (±5 min) post-dose
- 2 hours (±5 min) post-dose
- 4 hours (±30 min) post-dose
Days 36-37:
- Before TVB-2640 administration
- 2 hours (±5 min) post-dose
- 4 hours (±30 min) post-dose
- 6 hours (±30 min) post-dose
- 8 hours (±30 min) post-dose
- 24-hours (±1 hour) post-dose
Days 43-44:
- Before TVB-2640 administration
- 30 minutes (±5 min) post-dose
- 1 hour (±5 min) post-dose
- 2 hours (±5 min) post-dose
- 4 hours (±30 min) post-dose
- 6 hours (±30 min) post-dose
- 8 hours (±30 min) post-dose
- 24-hours (±1 hour) post-dose
Days 50-51:
- Before TVB-2640 administration
- 30 minutes (±5 min) post-dose
- 1 hour (±5 min) post-dose
- 2 hours (±5 min) post-dose
- 4 hours (±30 min) post-dose
- 6 hours (±30 min) post-dose
- 8 hours (±30 min) post-dose
- 24-hours (±1 hour) post-dose
Measured: Day 28; Days 36-37; Days 43-44; Days 50-51
Mean minimum serum concentration (Cmin) of TVB-2640
Peripheral blood will be drawn at the following times:
Day 28:
- Pre- enza dose
- 1 hours (±5 min) post-dose
- 2 hours (±5 min) post-dose
- 4 hours (±30 min) post-dose
Days 36-37:
- Before TVB-2640 administration
- 2 hours (±5 min) post-dose
- 4 hours (±30 min) post-dose
- 6 hours (±30 min) post-dose
- 8 hours (±30 min) post-dose
- 24-hours (±1 hour) post-dose
Days 43-44:
- Before TVB-2640 administration
- 30 minutes (±5 min) post-dose
- 1 hour (±5 min) post-dose
- 2 hours (±5 min) post-dose
- 4 hours (±30 min) post-dose
- 6 hours (±30 min) post-dose
- 8 hours (±30 min) post-dose
- 24-hours (±1 hour) post-dose
Days 50-51:
- Before TVB-2640 administration
- 30 minutes (±5 min) post-dose
- 1 hour (±5 min) post-dose
- 2 hours (±5 min) post-dose
- 4 hours (±30 min) post-dose
- 6 hours (±30 min) post-dose
- 8 hours (±30 min) post-dose
- 24-hours (±1 hour) post-dose
Measured: Day 28; Days 36-37; Days 43-44; Days 50-51
Mean minimum serum concentration (Cmin) of Enzalutamide
Peripheral blood will be drawn at the following times:
Day 28:
- Pre- enza dose
- 1 hours (±5 min) post-dose
- 2 hours (±5 min) post-dose
- 4 hours (±30 min) post-dose
Days 36-37:
- Before TVB-2640 administration
- 2 hours (±5 min) post-dose
- 4 hours (±30 min) post-dose
- 6 hours (±30 min) post-dose
- 8 hours (±30 min) post-dose
- 24-hours (±1 hour) post-dose
Days 43-44:
- Before TVB-2640 administration
- 30 minutes (±5 min) post-dose
- 1 hour (±5 min) post-dose
- 2 hours (±5 min) post-dose
- 4 hours (±30 min) post-dose
- 6 hours (±30 min) post-dose
- 8 hours (±30 min) post-dose
- 24-hours (±1 hour) post-dose
Days 50-51:
- Before TVB-2640 administration
- 30 minutes (±5 min) post-dose
- 1 hour (±5 min) post-dose
- 2 hours (±5 min) post-dose
- 4 hours (±30 min) post-dose
- 6 hours (±30 min) post-dose
- 8 hours (±30 min) post-dose
- 24-hours (±1 hour) post-dose
Measured: Day 28; Days 36-37; Days 43-44; Days 50-51
Mean TVB-2640 volume of distribution at steady state
Peripheral blood will be drawn at the following times:
Day 28:
- Pre- enza dose
- 1 hours (±5 min) post-dose
- 2 hours (±5 min) post-dose
- 4 hours (±30 min) post-dose
Days 36-37:
- Before TVB-2640 administration
- 2 hours (±5 min) post-dose
- 4 hours (±30 min) post-dose
- 6 hours (±30 min) post-dose
- 8 hours (±30 min) post-dose
- 24-hours (±1 hour) post-dose
Days 43-44:
- Before TVB-2640 administration
- 30 minutes (±5 min) post-dose
- 1 hour (±5 min) post-dose
- 2 hours (±5 min) post-dose
- 4 hours (±30 min) post-dose
- 6 hours (±30 min) post-dose
- 8 hours (±30 min) post-dose
- 24-hours (±1 hour) post-dose
Days 50-51:
- Before TVB-2640 administration
- 30 minutes (±5 min) post-dose
- 1 hour (±5 min) post-dose
- 2 hours (±5 min) post-dose
- 4 hours (±30 min) post-dose
- 6 hours (±30 min) post-dose
- 8 hours (±30 min) post-dose
- 24-hours (±1 hour) post-dose
Measured: Day 28; Days 36-37; Days 43-44; Days 50-51
Mean Enzalutamide volume of distribution at steady state
Peripheral blood will be drawn at the following times:
Day 28:
- Pre- enza dose
- 1 hours (±5 min) post-dose
- 2 hours (±5 min) post-dose
- 4 hours (±30 min) post-dose
Days 36-37:
- Before TVB-2640 administration
- 2 hours (±5 min) post-dose
- 4 hours (±30 min) post-dose
- 6 hours (±30 min) post-dose
- 8 hours (±30 min) post-dose
- 24-hours (±1 hour) post-dose
Days 43-44:
- Before TVB-2640 administration
- 30 minutes (±5 min) post-dose
- 1 hour (±5 min) post-dose
- 2 hours (±5 min) post-dose
- 4 hours (±30 min) post-dose
- 6 hours (±30 min) post-dose
- 8 hours (±30 min) post-dose
- 24-hours (±1 hour) post-dose
Days 50-51:
- Before TVB-2640 administration
- 30 minutes (±5 min) post-dose
- 1 hour (±5 min) post-dose
- 2 hours (±5 min) post-dose
- 4 hours (±30 min) post-dose
- 6 hours (±30 min) post-dose
- 8 hours (±30 min) post-dose
- 24-hours (±1 hour) post-dose
Measured: Day 28; Days 36-37; Days 43-44; Days 50-51
Mean time to maximum TVB-2640 serum concentration (Tmax) after administration
Peripheral blood will be drawn at the following times:
Day 28:
- Pre- enza dose
- 1 hours (±5 min) post-dose
- 2 hours (±5 min) post-dose
- 4 hours (±30 min) post-dose
Days 36-37:
- Before TVB-2640 administration
- 2 hours (±5 min) post-dose
- 4 hours (±30 min) post-dose
- 6 hours (±30 min) post-dose
- 8 hours (±30 min) post-dose
- 24-hours (±1 hour) post-dose
Days 43-44:
- Before TVB-2640 administration
- 30 minutes (±5 min) post-dose
- 1 hour (±5 min) post-dose
- 2 hours (±5 min) post-dose
- 4 hours (±30 min) post-dose
- 6 hours (±30 min) post-dose
- 8 hours (±30 min) post-dose
- 24-hours (±1 hour) post-dose
Days 50-51:
- Before TVB-2640 administration
- 30 minutes (±5 min) post-dose
- 1 hour (±5 min) post-dose
- 2 hours (±5 min) post-dose
- 4 hours (±30 min) post-dose
- 6 hours (±30 min) post-dose
- 8 hours (±30 min) post-dose
- 24-hours (±1 hour) post-dose
Measured: Day 28; Days 36-37; Days 43-44; Days 50-51
Mean time to maximum Enzalutamide serum concentration (Tmax) after administration
Peripheral blood will be drawn at the following times:
Day 28:
- Pre- enza dose
- 1 hours (±5 min) post-dose
- 2 hours (±5 min) post-dose
- 4 hours (±30 min) post-dose
Days 36-37:
- Before TVB-2640 administration
- 2 hours (±5 min) post-dose
- 4 hours (±30 min) post-dose
- 6 hours (±30 min) post-dose
- 8 hours (±30 min) post-dose
- 24-hours (±1 hour) post-dose
Days 43-44:
- Before TVB-2640 administration
- 30 minutes (±5 min) post-dose
- 1 hour (±5 min) post-dose
- 2 hours (±5 min) post-dose
- 4 hours (±30 min) post-dose
- 6 hours (±30 min) post-dose
- 8 hours (±30 min) post-dose
- 24-hours (±1 hour) post-dose
Days 50-51:
- Before TVB-2640 administration
- 30 minutes (±5 min) post-dose
- 1 hour (±5 min) post-dose
- 2 hours (±5 min) post-dose
- 4 hours (±30 min) post-dose
- 6 hours (±30 min) post-dose
- 8 hours (±30 min) post-dose
- 24-hours (±1 hour) post-dose
Measured: Day 28; Days 36-37; Days 43-44; Days 50-51
Mean Serum half-life (T1/2) of TVB-2640
Peripheral blood will be drawn at the following times:
Day 28:
- Pre- enza dose
- 1 hours (±5 min) post-dose
- 2 hours (±5 min) post-dose
- 4 hours (±30 min) post-dose
Days 36-37:
- Before TVB-2640 administration
- 2 hours (±5 min) post-dose
- 4 hours (±30 min) post-dose
- 6 hours (±30 min) post-dose
- 8 hours (±30 min) post-dose
- 24-hours (±1 hour) post-dose
Days 43-44:
- Before TVB-2640 administration
- 30 minutes (±5 min) post-dose
- 1 hour (±5 min) post-dose
- 2 hours (±5 min) post-dose
- 4 hours (±30 min) post-dose
- 6 hours (±30 min) post-dose
- 8 hours (±30 min) post-dose
- 24-hours (±1 hour) post-dose
Days 50-51:
- Before TVB-2640 administration
- 30 minutes (±5 min) post-dose
- 1 hour (±5 min) post-dose
- 2 hours (±5 min) post-dose
- 4 hours (±30 min) post-dose
- 6 hours (±30 min) post-dose
- 8 hours (±30 min) post-dose
- 24-hours (±1 hour) post-dose
Measured: Day 28; Days 36-37; Days 43-44; Days 50-51
Mean Serum half-life (T1/2) of Enzalutamide
Peripheral blood will be drawn at the following times:
Day 28:
- Pre- enza dose
- 1 hours (±5 min) post-dose
- 2 hours (±5 min) post-dose
- 4 hours (±30 min) post-dose
Days 36-37:
- Before TVB-2640 administration
- 2 hours (±5 min) post-dose
- 4 hours (±30 min) post-dose
- 6 hours (±30 min) post-dose
- 8 hours (±30 min) post-dose
- 24-hours (±1 hour) post-dose
Days 43-44:
- Before TVB-2640 administration
- 30 minutes (±5 min) post-dose
- 1 hour (±5 min) post-dose
- 2 hours (±5 min) post-dose
- 4 hours (±30 min) post-dose
- 6 hours (±30 min) post-dose
- 8 hours (±30 min) post-dose
- 24-hours (±1 hour) post-dose
Days 50-51:
- Before TVB-2640 administration
- 30 minutes (±5 min) post-dose
- 1 hour (±5 min) post-dose
- 2 hours (±5 min) post-dose
- 4 hours (±30 min) post-dose
- 6 hours (±30 min) post-dose
- 8 hours (±30 min) post-dose
- 24-hours (±1 hour) post-dose
Measured: Day 28; Days 36-37; Days 43-44; Days 50-51
Mean TVB-2640 clearance
Peripheral blood will be drawn at the following times:
Day 28:
- Pre- enza dose
- 1 hours (±5 min) post-dose
- 2 hours (±5 min) post-dose
- 4 hours (±30 min) post-dose
Days 36-37:
- Before TVB-2640 administration
- 2 hours (±5 min) post-dose
- 4 hours (±30 min) post-dose
- 6 hours (±30 min) post-dose
- 8 hours (±30 min) post-dose
- 24-hours (±1 hour) post-dose
Days 43-44:
- Before TVB-2640 administration
- 30 minutes (±5 min) post-dose
- 1 hour (±5 min) post-dose
- 2 hours (±5 min) post-dose
- 4 hours (±30 min) post-dose
- 6 hours (±30 min) post-dose
- 8 hours (±30 min) post-dose
- 24-hours (±1 hour) post-dose
Days 50-51:
- Before TVB-2640 administration
- 30 minutes (±5 min) post-dose
- 1 hour (±5 min) post-dose
- 2 hours (±5 min) post-dose
- 4 hours (±30 min) post-dose
- 6 hours (±30 min) post-dose
- 8 hours (±30 min) post-dose
- 24-hours (±1 hour) post-dose
Measured: Day 28; Days 36-37; Days 43-44; Days 50-51
Mean Enzalutamide clearance
Peripheral blood will be drawn at the following times:
Day 28:
- Pre- enza dose
- 1 hours (±5 min) post-dose
- 2 hours (±5 min) post-dose
- 4 hours (±30 min) post-dose
Days 36-37:
- Before TVB-2640 administration
- 2 hours (±5 min) post-dose
- 4 hours (±30 min) post-dose
- 6 hours (±30 min) post-dose
- 8 hours (±30 min) post-dose
- 24-hours (±1 hour) post-dose
Days 43-44:
- Before TVB-2640 administration
- 30 minutes (±5 min) post-dose
- 1 hour (±5 min) post-dose
- 2 hours (±5 min) post-dose
- 4 hours (±30 min) post-dose
- 6 hours (±30 min) post-dose
- 8 hours (±30 min) post-dose
- 24-hours (±1 hour) post-dose
Days 50-51:
- Before TVB-2640 administration
- 30 minutes (±5 min) post-dose
- 1 hour (±5 min) post-dose
- 2 hours (±5 min) post-dose
- 4 hours (±30 min) post-dose
- 6 hours (±30 min) post-dose
- 8 hours (±30 min) post-dose
- 24-hours (±1 hour) post-dose
Measured: Day 28; Days 36-37; Days 43-44; Days 50-51
Prostate-Specific Antigen (PSA) Response Rate
The PSA response rate will be evaluated using PCWG3 criteria and defined as the proportion of patients with a PSA decline of at least 50%. Any change from baseline is confirmed by a second measurement at least 3 weeks later. PSA Response Rate will be evaluated using PCWG3 criteria and defined as following: Percentage change from baseline in PSA to 12 weeks post Enzalutamide plus TVB-2640. Only evaluate for patients with at least 12 weeks of treatment, the PSA assessment at 12 weeks (84 days +/-3 days) will be used; Maximum percent decrease in PSA from baseline that occurs at any point after treatment.
Measured: Baseline; 12 weeks
Overall radiographic response rate
Tumor response will be evaluated using the PCWG3 criteria. Patients with measurable disease will be evaluated for clinical benefit as determined by tumor response using RECIST v1.1. Patients with non-measurable bone disease will be evaluated for progression based on the presence of any new lesions by bone scans. Radiographic tumor evaluation will be performed at screening and every 3 cycles or more frequently as determined by the investigator. Using the tumor response that is determined by the investigator, best overall response will be determined using RECIST v1.1. Best overall response is defined as the best response recorded from the start of treatment until disease progression or study exit. The overall response rate will be determined as the number of patients with a confirmed PR or CR divided by the total number of patients evaluable for overall response.
Measured: From baseline until disease progression for a maximum of 2 years from enrollment
Overall median progression free survival (PFS)
Overall progression free survival (PFS) is determined using the PCWG3 criteria. Overall PFS is measured from screening until the time that disease progression (radiographic progressive disease or clinical deterioration) or death is documented, whichever occurs first.
Measured: From baseline until disease progression or death from any cause for a maximum of 2 years from enrollment
Median radiographic progression free survival (PFS) as assessed by PCWG3
Radiographic progression-free survival (rPFS) is determined using the PCWG3 criteria to assess both soft-tissue and bone assessments. The rPFS is measured from screening until the time the first radiographic scan shows disease progression, or until the time of death, whichever occurs first. Patients who do not progress radiographically or did not die prior to study exit are censored on the date of their last dose of Enzalutamide plus TVB-2640. PFS will be summarized with a Kaplan-Meier curve. The Kaplan-Meier estimator will be used to determine the 6-month and 12-month PFS rates. Each estimate will have a corresponding 95% confidence interval. The median PFS will also be estimated with a corresponding 95% confidence interval
Measured: From baseline until disease progression for a maximum of 2 years from enrollment
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Feb 2023
- Study start20 Nov 2023
- Primary completion12 May 2026
- Study completion25 Jan 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Prostatic Neoplasms, Castration-ResistantStudies of the same condition, open and under way.
- More trials run by Weill Medical College of Cornell UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 8 participants (actual)
Sponsor and investigators
- Lead sponsor
- Weill Medical College of Cornell University
- Sponsor type
- University, hospital or other
- Collaborators
- Sagimet Biosciences Inc.
- Responsible party
- Sponsor
- Investigators
- David Nanus, M.D., Principal investigator, Weill Medical College of Cornell University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05743621
- Sponsor's protocol ID
- 22-08025117
- Status last verified
- Oct 2026
- First submitted
- 30 Jan 2023
- Last updated
- 26 Oct 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 26 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase I, Open-Label, Dose-Finding Study of TVB-2640 Administered in Combination With Enzalutamide (Xtandi) in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- ClinicalTrials.gov ID
- NCT05743621
- Acronym / sponsor ID
- 22-08025117
- Keywords
- Metastatic Castration-Resistant Prostate Cancer, FASN Inhibitor
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 8 participants (actual)
- Lead sponsor
- Weill Medical College of Cornell UniversityUniversity, hospital or other
- Collaborators
- Sagimet Biosciences Inc.
- Study start
- 20 Nov 2023 (actual)
- Primary completion
- 12 May 2026 (actual)
- Study completion
- 25 Jan 2028 (estimated)
- First posted
- 24 Feb 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to determine what effects (good and bad) Enzalutamide and TVB-2640 have in the treatment of prostate cancer whose prostate cancer has spread to other parts of their body and that has not gotten better with previous treatment. This study is a Phase I clinical trial. Phase I clinical trials test the side effects of an investigational drug or an investigational combination with another drug. "Investigational" means that the drug is still being studied and research doctors are trying to find out more about it. Although Enzalutamide is already being used to treat men with prostate cancer, combining Enzalutamide with TVB-2640 together in patients with prostate cancer is considered experimental. This research study is being done because additional effective treatments are needed for prostate cancer that has spread and is growing despite hormone suppression. By doing this study, the investigators hope to learn if combining Enzalutamide with TVB-2640 can be done safely. Participation in this research will last about 12 to 24 months after enrollment.
Detailed description
This phase I, open-label, dose-escalation study is designed to evaluate the dose limiting toxicities (DLTs) and maximum-tolerated dose (MTD) of TVB-2640 plus Enzalutamide and establish the TVB-2640 dose recommended for further investigation in phase 2 (i.e., recommended phase 2 dose [RP2D]). Patients with a confirmed histological or cytological diagnosis of prostate cancer (PC), evidence of metastatic PC on imaging (bone scan and/or CT/MRI scan), serum testosterone <50 ng/dl, who had progressed on androgen-depletion therapy (ADT), with documented progressive metastatic castration-resistant prostate cancer (mCRPC) based on Prostate Cancer Working Group 3 (PCWG3) criteria and no previously treatment with cytotoxic chemotherapy are eligible. This study represents the first clinical evaluation of TVB-2640 in combination with Enzalutamide. All patients will receive Enzalutamide monotherapy at the approved dose of 160 mg once daily for 28 days to reach the steady state as determined by measuring Enzalutamide and des-methyl-Enzalutamide levels. Participants who complete the Enzalutamide run-in period will begin oral TVB-2640 at the dose of 100 mg. The dose escalation scheme will be the Bayesian optimal interval (BOIN) design with additional dose levels of 100 mg, 150mg, 200 mg, 250 mg, and 300mg daily. The maximum sample size for the phase I will be 30 patients and the target DLT rate is 25% or less and a maximum of 9 patients at any dose level.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| TVB-2640 in combination with Enzalutamide | Experimental | Drug: TVB-2640, Drug: Enzalutamide |
Who may qualify
- Ages
- 18 years and older
- Sex
- Male only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (13 listed)
- Age >18 years
- Documented histological or cytological diagnosis of PC
- Evidence of metastatic PC on imaging (bone scan and/or CT/MRI scan)
- Diagnosis of progressive metastatic, castration resistant prostate cancer
- Potential participant must be planning to receive Enzalutamide as their first line of therapy for castration resistant prostate cancer or have previously received up to one line of Abiraterone or an androgen receptor antagonist
Key exclusion criteria (19 listed)
- Receipt of any type of biologic, or other systemic anticancer therapy (including investigational) except agents within 4 weeks before first dose of study treatment. Anti-resorptive bone agents are also allowed.
- Radiation therapy for bone metastasis within 2 weeks, any other radiation therapy within 4 weeks before first dose of study treatment. Systemic treatment with radionuclides within 6 weeks before the first dose of study treatment. Participants with clinically relevant ongoing complications from prior radiation therapy are not eligible.
- Prior exposure to taxane chemotherapy
- History of pneumonitis
- Known brain metastases or cranial epidural disease unless adequately treated with radiotherapy and/or surgery (including radiosurgery) and stable for at least 4 weeks prior to first dose of study treatment after radiotherapy or at least 4 weeks prior to first dose of study treatment after major surgery (e.g., removal or biopsy of brain metastasis). Participants must have complete wound healing from major surgery or minor surgery before first dose of study treatment. Eligible participants must be neurologically asymptomatic and without corticosteroid treatment for neurological indications at the time of first dose of study treatment.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| TVB-2640TVB- 2640 at 100 mg, 150mg, 200 mg, 250 mg, or 300mg daily, orally; dose determined by BOIN dose escalation per the protocol | Drug | TVB-2640 in combination with Enzalutamide |
| EnzalutamideAlso: Xtandi160 mg daily PO | Drug | TVB-2640 in combination with Enzalutamide |
Primary outcome
Optimal dose of TVB-2640 in combination with Enzalutamide, as determined by the maximum tolerated dose (MTD)
Time frame: From start of treatment to 28 days after start of TVB-2640 treatment
The maximum tolerated dose (MTD) is defined as the highest dose level at which ≤1 patient experiences a dose-limiting toxicity, as defined in the protocol (DLT). Once all the patients are accrued, the MTD will be determined by performing isotonic regression on the pooled data.
19 secondary outcomes
Number of adverse events (evaluated using the NCI CTCAE v5.0) of different doses of TVB-2640 in combination with Enzalutamide
Time frame: 12 months
Mean TVB-2640 total exposure (as measured by the area under the drug serum concentration vs. the time from administration curve [AUC])
Time frame: Day 28; Days 36-37; Days 43-44; Days 50-51
Mean Enzalutamide total exposure (as measured by the area under the drug serum concentration vs. the time from administration curve [AUC])
Time frame: Day 28; Days 36-37; Days 43-44; Days 50-51
Mean maximum serum concentration (Cmax) of TVB-2640
Time frame: Day 28; Days 36-37; Days 43-44; Days 50-51
Mean maximum serum concentration (Cmax) of Enzalutamide
Time frame: Day 28; Days 36-37; Days 43-44; Days 50-51
Mean minimum serum concentration (Cmin) of TVB-2640
Time frame: Day 28; Days 36-37; Days 43-44; Days 50-51
Mean minimum serum concentration (Cmin) of Enzalutamide
Time frame: Day 28; Days 36-37; Days 43-44; Days 50-51
Mean TVB-2640 volume of distribution at steady state
Time frame: Day 28; Days 36-37; Days 43-44; Days 50-51
Mean Enzalutamide volume of distribution at steady state
Time frame: Day 28; Days 36-37; Days 43-44; Days 50-51
Mean time to maximum TVB-2640 serum concentration (Tmax) after administration
Time frame: Day 28; Days 36-37; Days 43-44; Days 50-51
Mean time to maximum Enzalutamide serum concentration (Tmax) after administration
Time frame: Day 28; Days 36-37; Days 43-44; Days 50-51
Mean Serum half-life (T1/2) of TVB-2640
Time frame: Day 28; Days 36-37; Days 43-44; Days 50-51
Mean Serum half-life (T1/2) of Enzalutamide
Time frame: Day 28; Days 36-37; Days 43-44; Days 50-51
Mean TVB-2640 clearance
Time frame: Day 28; Days 36-37; Days 43-44; Days 50-51
Mean Enzalutamide clearance
Time frame: Day 28; Days 36-37; Days 43-44; Days 50-51
Prostate-Specific Antigen (PSA) Response Rate
Time frame: Baseline; 12 weeks
Overall radiographic response rate
Time frame: From baseline until disease progression for a maximum of 2 years from enrollment
Overall median progression free survival (PFS)
Time frame: From baseline until disease progression or death from any cause for a maximum of 2 years from enrollment
Median radiographic progression free survival (PFS) as assessed by PCWG3
Time frame: From baseline until disease progression for a maximum of 2 years from enrollment
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 26 Oct 2026.
- Individual participant dataSharing planned: No
Related trials for Prostatic Neoplasms, Castration-Resistant
RecruitingPhase 2
A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer
Metastatic Castration-Resistant Prostate Cancer
RecruitingPhase 1/2
Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer
Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
RecruitingObservational study
ARCTIC: Liquid Biomarkers in the Prospective Androgen Receptor Signaling Inhibitors (ARSI) Resistance Clinical Trials
Prostate Cancer, Prostate Adenocarcinoma
Active, not recruitingPhase 2
FPI-2265 (225Ac-PSMA-I&T) and Olaparib for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Metastatic Castration-resistant Prostate Cancer
Active, not recruitingPhase 2
Study of TGF-β Receptor Inhibitor Galunisertib (LY2157299) and Enzalutamide in Metastatic Castration-resistant Prostate Cancer
Prostate Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
David Nanus, M.D. principal investigator
Weill Medical College of Cornell University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing TVB-2640 and Enzalutamide in people with Prostatic Neoplasms, Castration-Resistant, run by Weill Medical College of Cornell University at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 13 inclusion and 19 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 26 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Optimal dose of TVB-2640 in combination with Enzalutamide, as determined by the maximum tolerated dose (MTD) (time frame: From start of treatment to 28 days after start of TVB-2640 treatment). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Oct 2026.